Cargando…

Evaluation of Homogentisic Acid, a Prospective Antibacterial Agent Highlighted by the Suitability of Nitisinone in Alkaptonuria 2 (SONIA 2) Clinical Trial

Despite urgent warnings about the spread of multidrug-resistant bacteria, the antibiotic development pipeline has remained sparsely populated. Naturally occurring antibacterial compounds may provide novel chemical starting points for antibiotic development programs and should be actively sought out....

Descripción completa

Detalles Bibliográficos
Autores principales:	Ooi, Nicola, Cooper, Ian R., Norman, Brendan, Gallagher, James A., Sireau, Nick, Bou-Gharios, George, Ranganath, Lakshminarayan R., Savage, Victoria J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341174/ https://www.ncbi.nlm.nih.gov/pubmed/37443717 http://dx.doi.org/10.3390/cells12131683

Ejemplares similares

Effects of Nitisinone on Oxidative and Inflammatory Markers in Alkaptonuria: Results from SONIA1 and SONIA2 Studies
por: Braconi, Daniela, et al.
Publicado: (2022)

Comparing nitisinone 2 mg and 10 mg in the treatment of alkaptonuria—An approach using statistical modelling
por: Ranganath, Lakshminarayan R., et al.
Publicado: (2021)

Determinants of tyrosinaemia during nitisinone therapy in alkaptonuria
por: Ranganath, L. R., et al.
Publicado: (2022)

Conditional targeting in mice reveals that hepatic homogentisate 1,2-dioxygenase activity is essential in reducing circulating homogentisic acid and for effective therapy in the genetic disease alkaptonuria
por: Hughes, Juliette H, et al.
Publicado: (2019)

Revisiting Quantification of Phenylalanine/Tyrosine Flux in the Ochronotic Pathway during Long-Term Nitisinone Treatment of Alkaptonuria
por: Ranganath, Lakshminarayan R., et al.
Publicado: (2022)

First decade anniversary of the United Kingdom National Alkaptonuria Centre
por: Khedr, Milad, et al.
Publicado: (2023)

Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria
por: Hughes, Juliette H., et al.
Publicado: (2020)

Impact of Nitisinone on the Cerebrospinal Fluid Metabolome of a Murine Model of Alkaptonuria
por: Davison, Andrew S., et al.
Publicado: (2022)

Comparing the Phenylalanine/Tyrosine Pathway and Related Factors between Keratopathy and No-Keratopathy Groups as Well as between Genders in Alkaptonuria during Nitisinone Treatment
por: Ranganath, Lakshminarayan R., et al.
Publicado: (2022)

Comprehensive Biotransformation Analysis of Phenylalanine-Tyrosine Metabolism Reveals Alternative Routes of Metabolite Clearance in Nitisinone-Treated Alkaptonuria
por: Norman, Brendan P., et al.
Publicado: (2022)

Expression of tyrosine pathway enzymes in mice demonstrates that homogentisate 1,2‐dioxygenase deficiency in the liver is responsible for homogentisic acid‐derived ochronotic pigmentation
por: Wilson, Peter J. M., et al.
Publicado: (2020)

Characterization of changes in the tyrosine pathway by 24-h profiling during nitisinone treatment in alkaptonuria
por: Ranganath, L.R., et al.
Publicado: (2022)

Nitisinone Treatment Affects Biomarkers of Bone and Cartilage Remodelling in Alkaptonuria Patients
por: Genovese, Federica, et al.
Publicado: (2023)

Vitiligo, alkaptonuria, and nitisinone—A report of three families and review of the literature
por: Ranganath, Lakshminarayan, et al.
Publicado: (2021)

Clinical development of nitisinone for alkaptonuria (developakure) - a rare disease clinical trials design
por: Psarelli, Eftychia Eirini, et al.
Publicado: (2013)

Radiological evolution of spinal disease in alkaptonuria and the effect of nitisinone
por: Imrich, Richard, et al.
Publicado: (2022)

Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria Centre
por: Ranganath, Lakshminarayan R., et al.
Publicado: (2020)

Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LC‐QTOF‐MS
por: Davison, Andrew S., et al.
Publicado: (2019)

Increased prevalence of Parkinson's disease in alkaptonuria
por: Ranganath, Lakshminarayan, et al.
Publicado: (2023)

Preventive use of nitisinone in alkaptonuria
por: Wolffenbuttel, Bruce H. R., et al.
Publicado: (2021)

Adequacy of nitisinone for the management of alkaptonuria
por: Abbas, Khawar, et al.
Publicado: (2022)

Molecular docking analysis of nitisinone with homogentisate 1,2 dioxygenase
por: Zolfaghari, Narges
Publicado: (2017)

Association of alkaptonuria and low dose nitisinone therapy with cataract formation in a large cohort of patients
por: Ahmad, Mohammad S. Z., et al.
Publicado: (2022)

Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria
por: Milan, A. M., et al.
Publicado: (2019)

Assessing the effect of nitisinone induced hypertyrosinaemia on monoamine neurotransmitters in brain tissue from a murine model of alkaptonuria using mass spectrometry imaging
por: Davison, A. S., et al.
Publicado: (2019)

Data on items of AKUSSI in Alkaptonuria collected over three years from the United Kingdom National Alkaptonuria Centre and the impact of nitisinone
por: Griffin, R., et al.
Publicado: (2018)

Long‐term low dose nitisinone therapy in adults with alkaptonuria shows no cognitive decline or increased severity of depression
por: Davison, Andrew S., et al.
Publicado: (2022)

Correction to: Assessing the effect of nitisinone induced hypertyrosinaemia on monoamine neurotransmitters in brain tissue from a murine model of alkaptonuria using mass spectrometry imaging
por: Davison, Andrew S., et al.
Publicado: (2019)

A patient survey on the impact of alkaptonuria symptoms as perceived by the patients and their experiences of receiving diagnosis and care
por: Rudebeck, Mattias, et al.
Publicado: (2020)

Fatal acute haemolysis and methaemoglobinaemia in a man with renal failure and Alkaptonuria – Is nitisinone the solution?
por: Davison, A.S., et al.
Publicado: (2020)

Homogentisate 1,2 Dioxygenase is Expressed in Human Osteoarticular Cells: Implications in Alkaptonuria
por: Laschi, Marcella, et al.
Publicado: (2012)

First Report of a Deletion Encompassing an Entire Exon in the Homogentisate 1,2-Dioxygenase Gene Causing Alkaptonuria
por: Habbal, Mohammad Zouheir, et al.
Publicado: (2014)

Metabolomic studies in the inborn error of metabolism alkaptonuria reveal new biotransformations in tyrosine metabolism
por: Norman, Brendan P., et al.
Publicado: (2021)

Alkaptonuria: Current Perspectives
por: Zatkova, Andrea, et al.
Publicado: (2020)

Homogentisate 1,2-dioxygenase (HGD) gene variants in young Egyptian patients with alkaptonuria
por: Abdelkhalek, Zeinab S., et al.
Publicado: (2023)

Development of an Effective Therapy for Alkaptonuria – Lessons for Osteoarthritis
por: Gallagher, James A., et al.
Publicado: (2021)

Pigmentation Chemistry and Radical‐Based Collagen Degradation in Alkaptonuria and Osteoarthritic Cartilage
por: Chow, Wing Ying, et al.
Publicado: (2020)

Analysis of the Phenotype Differences in Siblings with Alkaptonuria
por: Zatkova, Andrea, et al.
Publicado: (2022)

Clinical development innovation in rare diseases: overcoming barriers to successful delivery of a randomised clinical trial in alkaptonuria—a mini-review
por: Ranganath, L. R., et al.
Publicado: (2023)

Fatal oxidative haemolysis and methaemoglobinaemia in a patient with alkaptonuria and acute kidney injury
por: Mullan, Adam, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_508r8j646jir6qqk00vdkmp5cr